Literature DB >> 12325040

Effect of acute and chronic administration of the selective 5-HT2C receptor antagonist SB-243213 on midbrain dopamine neurons in the rat: an in vivo extracellular single cell study.

Thomas P Blackburn1, Yoshio Minabe, Derek N Middlemiss, Yukihiko Shirayama, Kenji Hashimoto, Charles R Ashby.   

Abstract

In this study, we examined the effect of the acute and chronic administration of the selective 5-HT2C receptor antagonist SB-243213 (SB) on the activity of spontaneously active dopamine (DA) cells in the substantia nigra pars compacta (SNC) and ventral tegmental area (VTA) in anesthetized, albino, male Sprague-Dawley rats. This was accomplished using the technique of in vivo extracellular single cell recording. The acute i.v. administration of SB-243213 (0.025-3.2 mg/kg) did not significantly alter the basal firing rate or pattern of either spontaneously active SNC or VTA DA neurons compared to vehicle-treated controls. The acute i.p. administration of either 1 or 10 mg/kg of SB-243213 did not significantly alter the number of spontaneously active DA cells in the SNC or VTA compared to vehicle-treated controls, whereas the 3 mg/kg dose only significantly decreased the number of spontaneously active VTA DA neurons. Overall, the 1 mg/kg dose of SB-243213 did not significantly alter the firing pattern of either SNC or VTA DA neurons compared to vehicle-treated controls. In contrast, the 3 mg/kg dose significantly altered the firing pattern of SNC DA neurons, whereas the 10 mg/kg dose altered the firing pattern of DA neurons in both the SNC and VTA. The repeated i.p. administration (21 days) of 1, 3, and 10 mg/kg of SB-243213 or 20 mg/kg of clozapine produced a significant decrease in the number of spontaneously active DA cells in the VTA compared to vehicle-treated controls. The decrease in the number of spontaneously active VTA DA cells was not reversed by the i.v. administration of (+)-apomorphine (50 microg/kg). The repeated administration of either 1 or 3 mg/kg of SB-243213 had minimal effects on the firing pattern of either SNC or VTA DA neurons. In contrast, the firing pattern of VTA DA neurons was significantly altered by 10 mg/kg dose of SB-243213. Overall, our results indicate that antagonism of the 5-HT2C receptor alters the activity of midbrain DA neurons in anesthetized rats and suggest that SB-243213 has an atypical antipsychotic profile following chronic administration. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12325040     DOI: 10.1002/syn.10116

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  5 in total

Review 1.  Multiple controls exerted by 5-HT2C receptors upon basal ganglia function: from physiology to pathophysiology.

Authors:  P De Deurwaerdère; M Lagière; M Bosc; S Navailles
Journal:  Exp Brain Res       Date:  2013-04-25       Impact factor: 1.972

2.  Role of 5-HT receptor mechanisms in sub-chronic PCP-induced reversal learning deficits in the rat.

Authors:  Samantha L McLean; Marie L Woolley; Dave Thomas; Joanna C Neill
Journal:  Psychopharmacology (Berl)       Date:  2009-07-21       Impact factor: 4.530

3.  Impact of serotonin 2C receptor null mutation on physiology and behavior associated with nigrostriatal dopamine pathway function.

Authors:  Luna Abdallah; Stephen J Bonasera; F Woodward Hopf; Laura O'Dell; Marco Giorgetti; Minke Jongsma; Scott Carra; Massimo Pierucci; Giuseppe Di Giovanni; Ennio Esposito; Loren H Parsons; Antonello Bonci; Laurence H Tecott
Journal:  J Neurosci       Date:  2009-06-24       Impact factor: 6.167

4.  Electrophysiological effects of repeated administration of agomelatine on the dopamine, norepinephrine, and serotonin systems in the rat brain.

Authors:  Franck Chenu; Mostafa El Mansari; Pierre Blier
Journal:  Neuropsychopharmacology       Date:  2012-08-08       Impact factor: 7.853

Review 5.  Reward processing by the dorsal raphe nucleus: 5-HT and beyond.

Authors:  Minmin Luo; Jingfeng Zhou; Zhixiang Liu
Journal:  Learn Mem       Date:  2015-08-18       Impact factor: 2.460

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.